SMO and neoplasm: These data highlight two important concerns when considering vismodegib for advanced opBCC: 1) primary resistance, in which the treatment naïve tumor has a mutation downstream of PTCH1, or 2) secondary resistance, in which tumors acquire or select for mutations that circumvent SMO inhibition.